SER AMEX
Serina Therapeutics, Inc.
1W: -6.2%
1M: -25.2%
3M: +0.5%
YTD: -5.8%
1Y: -62.7%
3Y: -92.4%
5Y: -94.3%
$1.96
+0.01 (+0.51%)
Weekly Expected Move ±11.0%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
21 relationships21
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-11-09
Earliest Filing
2025-04-29
Latest Filing
partner: 9
customer: 6
investor: 2
target: 2
acquirer: 2
Counterparties (Filed by SER)
21 relationshipsCompanies named in SER's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| JonesTrading Institutional Services LLC | — | partner | Sales agent for at the market offering program | 2025-04-29 | View |
| JuvVentures (UK) Limited | — | investor | Purchased all outstanding shares of UniverXome Bioengineering, Inc. and assumed secured debt. | 2024-12-26 | View |
| UniverXome Bioengineering, Inc. | — | target | Wholly-owned subsidiary of Serina Therapeutics, Inc. that was sold to JuvVentures. | 2024-12-26 | View |
| ReCyte Therapeutics, Inc. | — | partner | Wholly-owned subsidiary of UniverXome Bioengineering, Inc. involved in stem cell-derived research. | 2024-12-26 | View |
| Reverse Bioengineering, Inc. | — | partner | Wholly-owned subsidiary of UniverXome Bioengineering, Inc. involved in cellular reprogramming technology. | 2024-12-26 | View |
| JuvVentures (UK) Limited | — | investor | Strategic shareholder providing $10 million equity financing | 2024-12-02 | View |
| Enable Injections | — | partner | Strategic partner providing enFuse wearable drug delivery platform | 2024-12-02 | View |
| Pfizer, Inc. | PFE | partner | Licensee granted non-exclusive license to use POZ polymer technology | 2024-12-02 | View |
| AgeX Therapeutics, Inc. | — | customer | Borrower in the convertible promissory note amendment | 2024-04-01 | View |
| Serina Therapeutics, Inc. | SER | target | Target company in the Serina Merger | 2024-04-01 | View |
| Canaria Transaction Corporation | — | acquirer | Acquirer in the Serina Merger | 2024-04-01 | View |
| Reverse Bioengineering, Inc. | — | partner | Guarantor of the loan obligations | 2024-04-01 | View |
| Recyte Therapeutics, Inc. | — | partner | Guarantor of the loan obligations | 2024-04-01 | View |
| Univerxome Bioengineering, Inc. | — | partner | Guarantor of the loan obligations | 2024-04-01 | View |
| AgeX Therapeutics Inc. | — | customer | Borrower in a convertible promissory note amendment | 2023-08-04 | View |
| AgeX Therapeutics, Inc. | — | acquirer | Company entering exchange agreement to convert loans into preferred stock | 2023-07-21 | View |
| AgeX Therapeutics Inc. | — | customer | Borrower in a convertible promissory note amendment | 2023-06-08 | View |
| AGEX THERAPEUTICS, INC. | — | customer | Borrower issued a secured convertible promissory note to the Lender. | 2023-02-10 | View |
| AGEX THERAPEUTICS, INC. | — | customer | Issued a Secured Convertible Promissory Note to obtain a loan facility. | 2022-02-15 | View |
| Reverse Bioengineering Inc. | — | partner | Designated as a related entity permitted to enter into specific convertible note financing. | 2022-02-15 | View |
| Agex Therapeutics Inc. | — | customer | Borrower in a loan facility agreement amendment | 2021-11-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-09 | Other Events; Exhibits | View | |
| 2026-08-27 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-23 | Officer/Director Change; Exhibits | View | |
| 2026-07-22 | Officer/Director Change | View | |
| 2026-06-24 | Bylaws Amendment; Shareholder Vote | View | |
| 2026-04-21 | Officer/Director Change; Bylaws Amendment | View | |
| 2026-03-25 | Earnings Release; Exhibits | View | |
| 2026-03-23 | Material Agreement; Unregistered Equity Sales; Officer/Director Change; Bylaws Amendment; Regulation | Agreement | View |
| 2026-01-28 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-15 | Notice of Delisting or Transfer; Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-12 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-11-03 | Other Events | View | |
| 2025-10-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-15 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-09-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-22 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR